Listened to the above webinar which mostly went above my head. One thought that was triggered from that discussion is that Race may initiate some work to develop a biomarker tool to identify patients who may benefit from including Zantrene along with the anthracyclines for better cardio-protection. That way it can only be administered to patients who can benefit from it rather than everyone undergoing anthracycline treatments.
As a separate thought, could patients undergoing radiation therapy and at risk of cardio toxicity be given Zantrene for cardio protection?
Ann: Uni of Newcastle Heart Protection Collaboration Extended, page-22
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |